2 International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 55: solar and ultraviolet radiation. Lyon: International Agency for Research on Cancer; 1992.
9 National Health and Medical Research Council. Clinical practice guidelines for the management of cutaneous melanoma. Canberra: The Council; 1999. [cited 16 May 2003]. Available from url: http://www.health.gov.au/nhmrc/publications/pdf/cp68.pdf [section 2.3] [section 4.3] [section 4.3.1]
11 Richard MA, Martin S, Gouvernet J, Folchetti G, Bonerandi JJ, Grob JJ. Humour and alarmism in melanoma prevention: a randomized controlled study of three types of information leaflet. Br J Dermatol 1999;140:909-14.
15 Hanrahan PF, Hersey P, Menzies SW, Watson AB, D’Este CA. Examination of the ability of people to identify early changes of melanoma in computer-altered pigmented skin lesions. Arch Dermatol 1997;133:301-11.
16 Kiekbusch S, Hannich HJ, Isacsson A, Johannisson A, Lindholm LH, Sager E, et al. Impact of a cancer education multimedia device on public knowledge, attitudes, and behaviors: a controlled intervention study in Southern Sweden. Cancer Educ 2000;15:232-6.
18 Bastuji-Garin S, Grob JJ, Grognard C, Grosjean F, Guillaume JC. Melanoma prevention: evaluation of a health education campaign for primary schools. Arch Dermatol 1999;135:936-40. [section 2.3.1] [section 7.9.3]
19 Helfand M, Mahon S, Eden K. Screening for skin cancer. Rockville (MD): Agency for Healthcare Research and Quality; 2001. Systematic evidence review No. 2. AHRQ publication No. 01-S002. [cited 16 May 2003]. Available from url: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowSection&rid=hstat3.chapter.711 [section 2.4.1] [section 2.4.2] [section 2.4.5]
25 Harris V, Sandridge A, Black RJ, Brewster DH, Gould A. Cancer Registration Statistics Scotland, 1986 - 1995. Edinburgh: National Health Service in Scotland, Information and Statistics Division; 1998.
30 Melia J, Moss S, Coleman D, Frost T, Graham-Brown R, Hunter JAA, et al. The relation between mortality from malignant melanoma and early detection in the Cancer Research Campaign Mole Watcher Study. Br J Cancer 2001;85:803-7.
32 Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-51.
35 Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 2001;85:836-44.
40 Fitzpatrick TB, Rhodes AR, Sober AJ, Mihm MC. Primary malignant melanoma of the skin: the call for action to identify persons at risk; to discover precursor lesions; to detect early melanomas. Pigment Cell 1988;9:110-7.
41 Duff CG, Melsom D, Rigby HS, Kenealy JM, Townsend PL. A 6 year prospective analysis of the diagnosis of malignant melanoma in a pigmented-lesion clinic: even the experts miss malignant melanomas, but not often. Br J Plast Surg 2001;54:317-21. [section 3.2] [section 3.3]
42 Richard MA, Grob JJ, Avril MF, Delaunay M, Gouvernet J, Wolkenstein P, et al. Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer 2000:20;89:280-5. [section 3.2] [section 3.3]
43 Gerbert B, Maurer T, Berger T, Pantilat S, McPhee SJ, Wolff M, et al. Primary care physicians as gatekeepers in managed care. Primary care physicians’ and dermatologists’ skills at secondary prevention of skin cancer. Arch Dermatol 1996;132:1030-8.
44 Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001;137:1343-50.
46 Binder M, Schwarz M, Winkler A, Steiner
A, Kaider A, Wolff K, et al. Epiluminescence microscopy. A useful tool for the
diagnosis of pigmented skin lesions for formally trained dermatologists. Arch
48 Maurer J, Knollmann FD, Schlums D, Garbe C, Vogl TJ, Bier J, et al. Role of high-resolution magnetic resonance imaging for differentiating melanin-containing skin tumors. Invest Radiol 1995;30:638-43.
50 Chwirot BW, Chwirot S, Redzinski J, Michniewicz Z. Detection of melanomas by digital imaging of spectrally resolved ultraviolet light-induced autofluorescence of human skin. Eur J Cancer 1998;34:1730-4.
52 O’Donnell B, Dervan P, Codd M, Powell F, Lawlor D, O’Loughlin S. A clinicopathological correlation of 134 stage 1 and 79 non-invasive cutaneous melanomas presenting over a decade (1984-1993) at the Mater Misericordiae Hospital, Dublin. Ir J Med Sci 1998;167:132-5.
62 Calonje E. ACP best practice no 162. The histological reporting of melanoma. Association of Clinical Pathologists. J Clin Pathol 2000;53:587-90. [section 3.5] [section 3.7.1] [section 3.8.1] [section 4.1.1]
63 Griffiths RW, Briggs JC. Biopsy procedures, primary wide excisional surgery and long term prognosis in primary clinical stage I invasive cutaneous malignant melanoma. Ann R Coll Surg Engl 1985;67:75-8.
71 Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtner CM, Peter RU, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000;43:477-82.
75 Cochran AJ, Elashoff D, Morton DL, Elashoff R. Individualized prognosis for melanoma patients. Hum Pathol 2000;31:327-31. [section 3.8.1] [section 3.8.2] [section 3.8.4] [section 3.8.6] [section 3.8.7] [section 3.8.8] [section 3.8.9] [section 3.8.11]
76 Clark WH Jr, Elder DE, Guerry D 4th, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904. [section 3.8.1] [section 3.8.2] [section 3.8.3] [section 3.8.4] [section 3.8.6] [section 3.8.7] [section 3.8.8] [section 3.8.9] [section 3.8.11]
77 Cascinelli N, Zurrida S, Galimberti V, Bartoli C, Bufalino R, Del Prato I, et al. Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol 1994;20:817-22.
79 Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86:761-9.
81 Spatz A, Shaw HM, Crotty KA, Thompson JF, McCarthy SW. Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (> 5 mm). Histopathology 1998;33:406-13.
82 Guerry D 4th, Synnestvedt M, Elder DE, Schultz D. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993;100:342S-5S. [section 3.8.3] [section 7.2]
86 Buttner P, Garbe C, Bertz J, Burg G, d’Hoedt
B, Drepper H, et al. Primary cutaneous melanoma. Optimized cutoff points of
tumor thickness and importance of Clark’s level for prognostic classification.
87 Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology 1990;17:389-95. [section 3.8.5] [section 3.8.9]
89 Day CL Jr, Mihm MC Jr, Lew RA, Harris MN, Kopf AW, Fitzpatrick TB, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg 1982;195:35-43.
90 Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res 2000;10:153-64. [section 3.8.2] [section 3.8.7] [section 3.8.10]
94 Corona R, Mele A, Amini M, De Rosa G, Coppola G, Piccardi P, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996;14:1218-23.
97 Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol 2002;8:2053-7.
100 Gutzmer R, Kaspari M, Brodersen JP, Mommert S, Volker B, Kapp A, et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology 2002;41:510-8.
101 Urist MM, Balch CM, Soong S, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985;55:1398-402.
102 Welvaart K, Hermans J, Zwaveling A, Ruiter DJ. Prognoses and surgical treatment of patients with stage I melanomas of the skin: a retrospective analysis of 211 patients. J Surg Oncol 1986;31:79-86.
105 Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 melanoma. N Engl J Med 1988;318:1159-62.
106 Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2-melanoma surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262-9.
107 Cohn-Cedarmark G, Rutquist LE, Andersson R, Breivald M, Ingvar C, Johansson H, et al. Long term results of a randomized study by the Swedish melanoma study group on 2 melanoma versus 5 melanoma resection margins for patients with cutaneous melanoma with a tumour thickness of 0.8-2.0mm. Am Cancer Soc 2000;89:1495-501.
108 Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S, et al. Resection margins of 2 versus 5 melanoma for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996;77:1809-14.
109 Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 1998;5:322-8.
110 Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48. [section 3.8.4] [section 3.8.5] [section 3.8.6] [section 3.8.7] [section 3.8.10] [section 4.1] [section 4.2] [section 5.2]
113 Balch CM, Soong SJ, Gershwinwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34. [section 4.3] [section 4.3.2]
119 Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193:377-88.
120 Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 1991;214:627-36. [section 4.3] [section 4.3.2]
126 Drepper H, Kohler CO, Bastian B, Breuninger H, Brocker EB, Gohl J, et al. Benefit of elective lymph node dissection in sub groups of melanoma patients. Results of a multicentre study of 3616 patients. Cancer 1993;72:741-9.
130 Veronesi U, Adamus J, Bandiera DC, Brennhovd O, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
131 Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
132 Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7:87-97.
135 Bostick P, Essner R, Glass E, Kelley M, Sarantou T, Foshag LJ, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999;134:43-9.
136 Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998;124:203-10.
137 Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-65.
140 Clary BM, Mann B, Brady MS, Lewis JJ, Coit DG. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 2001;8:328-37.
143 Lejeune FJ. Isolation perfusion of the limbs for malignant melanoma. In: 38th Clinical Conference, Advances in the Biology and Clinical Management of Melanoma. February 21-24, Houston, Texas. Houston (TX): MD Anderson Cancer Center; 1995. p. 13-14.
144 Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906-12.
145 Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491-502.
153 Bossi MC, Sanvito S, Lovati E, De Fiori E, Testori A, Bellomi M. Role of high resolution color-Doppler US of the sentinel node in patients with stage I melanoma [Italian]. Radiol Med (Torino) 2001;102:357-62.
155 Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local- regional metastases of melanoma. J Clin Oncol 1995;13:2104-8. [section 5.1.3] [section 7.9.3]
156 Huang CL, Provost N, Marghoob AA, Levin L, Bart RS. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 1998;39:451-63. [section 5.2] [section 7.9.1]
161 O’Brien CJ, Petersen-Schaefer K, Stevens GN, Bass PC, Tew P, Gebski VJ, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997;19:589-94.
164 Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler RA, Garden AS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994;30:795-8.
165 Creagan ET, Cupps RE, Ivins JC, Pritchard DJ, Sim FH, Soule EH, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 1978;42:2206-10.
166 Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-83.
167 Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 1995;87:1710-3.
168 Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
169 Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-10.
170 Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:1425-9.
171 Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
173 Eggermont AM, Keilholz U, Testori A, Cook M, Lienard D, Ruiter DJ. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. Ann Surg Oncol 2001;8:38S-40S.
174 Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866-9.
176 Wallack MK, Sivanandham M, Balch, Urist MM, Bland KI, Murray D, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69-77.
177 Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181-90.
178 Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80
179 Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999;140:249-54. [section 7.1] [section 7.2] [section 7.4] [section 7.5.1] [section 7.5.2] [section 7.5.3] [section 7.8] [section 7.9]
180 Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O’Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:1703-5. [section 7.1] [section 7.3] [section 7.9] [section 7.9.1] [section 7.9.3]
181 Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995;19:199-203. [section 7.1] [section 7.3] [section 7.5.1] [section 7.5.2] [section 7.5.3] [section 7.9] [section 7.9.1] [section 7.9.3] [section 11.2.5]
183 Mooney MM, Kulas M, McKinley B, Michalek AM, Kraybill WG. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol 1998;5:54-63. [section 7.1] [section 7.3] [section 7.9] [section 7.9.3]
184 Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985;13:756-60. [section 7.1] [section 7.3] [section 7.4] [section 7.5.1] [section 7.5.3]
185 McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow up. Surg Gynecol Obstet 1988;166:497-502. [section 7.1] [section 7.3] [section 7.4] [section 7.5.1] [section 7.5.2] [section 7.5.3] [section 7.8]
186 Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow up in stage 1 cutaneous malignant melanoma: an audit. Clin Oncol 1993;5:174-80. [section 7.1] [section 7.3] [section 7.5.1] [section 7.5.2] [section 7.5.3] [section 7.9]
187 Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003;21:520-9. [section 7.1] [section 7.3] [section 7.5.1] [section 7.5.2] [section 7.9] [section 7.9.1] [section 7.9.3]
188 Martini L, Brandini P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow up schedule. Tumori 1994;80:188-97. [section 7.3] [section 7.4] [section 7.5.1] [section 7.5.2] [section 7.5.3]
196 Jillella A, Mani S, Nair B, Poo WJ, Bolognia J, Ariyan S, et al. The role for close follow-up of melanoma patients with AJCC stages l-lll: a preliminary analysis [abstract]. Proc Am Soc Clin Oncol 1995;14:413.
199 Franzke A, Probst-Kepper M, Buer J. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998;78:40-5. [section 7.9] [section 7.9.1]
205 Johnson TM, Fader DJ, Chang AE, Yahanda A, Smith JW 2nd, Hamlet KR, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997;4:396-402.
206 Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782-93. [section 8] [section 8.1]
207 Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1:126-34.
208 Brand CU, Ellwanger U, Stroebel W, Meier
F, Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer
for patients with disseminated melanoma. An analysis of related prognostic factors.
1997;79:2345-53. [section 8] [section 8.1]
212 Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001;11:75-81.
213 Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
214 Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
216 Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743-51.
217 Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999;85:1979-84.
218 Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999;22:145-54.
219 Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001;84:1036-42.
222 Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys 1998;42:161-7.
226 Levack P, Collie D, Gibson A, Graham J, Grant R, Hurman D, et al. A prospective audit of the diagnosis, management and outcome of malignant cord compression. Edinburgh: Scottish Executive Department of Health, Clinical Resources and Audit Group; 2001. [cited 16 May 2003]. Available from url: http://www.show.scot.nhs.uk/crag/committees/CEPS/reports/F%20Report%20copy%206-2-02.PDF
227 Scottish Executive Department of Health. Scottish referral guidelines for suspected cancer. Edinburgh: The Department; 2002. [cited 16 May 2003]. Available from url: http://www.show.scot.nhs.uk/sehd/cancerinscotland/Documents/Scottish%20Referral%20Guidelines%20for%20suspected%20cancer.pdf
229 Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803.
232 Grob JJ, Regis J, Laurans R, Delaunay M, Wolkenstein P, Paul K, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Cancer 1998;34:1187-92.
233 General Medical Council. Tomorrow’s doctors. Recommendations on undergraduate medical education. London: The Council; 2002. [cited 16 May 2003]. Available from url: http://www.gmc-uk.org/med_ed/tomdoc.htm
234 Clinical Standards Board for Scotland. Clinical standards. Specialist palliative care. Revised ed. Edinburgh: The Board; 2002. [cited 16 May 2003]. Available from url: http://www.clinicalstandards.org/pdf/finalstand/SPC.pdf
235 Scottish Intercollegiate Guidelines Network (SIGN). Control of pain in patients with cancer. Edinburgh: SIGN; 2000. (SIGN guideline no. 44).
236 Addington-Hall JM, MacDonald LD, Anderson HR, Chamberlain J, Freeling P, Bland JM, et al. Randomised controlled trial of effects of coordinating care for terminally ill cancer patients. BMJ 1992;305:1317-22.
237 Raftery JP, Addington-Hall JM, MacDonald LD, Anderson HR, Bland JM, Chamberlain J, et al. A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Palliat Med 1996;10:151-61.
251 Lederman JS, Lew RA, Koh HK, Sober AJ. Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. J Natl Cancer Inst 1985;74:981-5. [section 9.2] [section 9.3]
252 Osterlind A, Tucker MA, Stone BJ, Jensen OM.The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988;42:821-4. [section 9.2] [section 9.3]
256 Le MG, Cabanes PA, Desvignes V, Chanteau MF, Mlika N, Avril MF. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 1992;3:199-205.
258 Brandberg Y, Bergenmar M, Bolund C, Michelson H, Mansson-Brahme E, Ringborg U, et al. Information to patients with malignant melanoma: a randomised group study. Patient Educ Couns 1994;23:97-105. [section 3.8.2] [section 10.3] [section 10.4]
261 Brandberg Y, Bergenmar M, Michelson H, Mansson-Brahme E, Sjoden PO. Six-month follow-up of effects of an information programme for patients with malignant melanoma. Patient Educ Couns 1996;28:201-8.
262 Scottish Executive Department of Health. Introduction of managed clinical networks within the NHS in Scotland. (NHS MEL(1999)10). Edinburgh: The Department; 1999. [cited 16 May 2003]. Available from url: http://www.show.scot.nhs.uk/sehd/mels/1999_10.htm
265 Beddingfield FC. Melanoma: a decision analysis to estimate the effectiveness and cost-effectiveness of screening and an analysis of the relevant epidemiology of the disease [dissertation]. Santa Monica (CA): RAND; 2002. [cited 16 May 2003]. Available from url: http://www.rand.org/publications/RGSD/RGSD167/
266 Brobeil A, Cruse CW, Messina JL, Glass LF, Haddad FF, Berman CG, et al. Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. Surg Oncol Clin N Am 1999;8:435-45,viii.
269 Ghersi D, Howard K, Irwig L, Salkeld G, Simes J. Positron emission tomography. Canberra: Medicare Services Advisory Committee; 2001. [cited 16 May 2003]. Available from url: http://www.health.gov.au/msac/pdfs/msacref02.pdf
271 Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997;15:2351-8.
272 Gonzalez-Larriba JL, Serrano S, Alvarez-Mon M, Camacho F, Casado MA, Diaz-Perez JL, et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer 2000;36:2344-52.
273 Shepherd J, Milne R. The use of interferon alfa in the treatment of metastatic cutaneous melanoma. Southampton: Wessex Institute for Health Research and Development; 1999. Development and evaluation committee report No. 99.
275 Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients—monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002;87:151-7.
276 Scottish Executive Health Department. Cancer in Scotland: action for Change. Edinburgh: The Executive; 2001. [cited 16 May 2003]. Available from url: http://www.scotland.gov.uk/library3/health/csac-00.asp